Headlands Technologies LLC Has $314,000 Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Key Points

• Headlands Technologies LLC significantly reduced its stake by 59.9% in Agios Pharmaceuticals during the 1st quarter, now holding 10,715 shares valued at approximately $314,000.
• Analysts have recently downgraded Agios Pharmaceuticals, with Wall Street Zen changing their rating from "hold" to "sell", while the average target price for the stock is currently $56.33.
• Agios Pharmaceuticals reported worse-than-expected earnings for the last quarter, with a loss of $1.93 per share compared to analysts' estimates of a loss of $1.74.

Headlands Technologies LLC decreased its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 59.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,715 shares of the biopharmaceutical company's stock after selling 16,021 shares during the quarter. Headlands Technologies LLC's holdings in Agios Pharmaceuticals were worth $314,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in AGIO. GF Fund Management CO. LTD. bought a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $39,000. CWM LLC increased its position in Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 996 shares during the period. Sterling Capital Management LLC lifted its stake in Agios Pharmaceuticals by 818.0% in the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after buying an additional 1,587 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Agios Pharmaceuticals by 16.2% during the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock valued at $105,000 after acquiring an additional 499 shares during the period. Finally, Summit Investment Advisors Inc. grew its position in shares of Agios Pharmaceuticals by 7.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock worth $194,000 after acquiring an additional 394 shares during the last quarter.

Agios Pharmaceuticals Trading Down 0.4%

NASDAQ:AGIO traded down $0.15 during midday trading on Thursday, hitting $36.46. 79,855 shares of the stock were exchanged, compared to its average volume of 712,075. The company has a market capitalization of $2.12 billion, a price-to-earnings ratio of 3.31 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58. The business has a 50-day moving average price of $36.38 and a two-hundred day moving average price of $32.73.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. The firm had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.46 million. Sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Tsveta Milanova sold 2,770 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $92,905.80. Following the completion of the sale, the insider directly owned 26,122 shares in the company, valued at approximately $876,131.88. This trade represents a 9.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David Scadden sold 1,400 shares of the firm's stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $40.00, for a total value of $56,000.00. Following the sale, the director directly owned 17,603 shares of the company's stock, valued at approximately $704,120. This represents a 7.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 57,448 shares of company stock worth $2,026,141. Company insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Bank of America reduced their target price on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Scotiabank reduced their price objective on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a research report on Monday, July 28th. Finally, Wall Street Zen lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, Agios Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $56.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.